Adebrelimab
Metastatic Malignant Neoplasm In The Colon
Explore 65 assets in Metastatic Malignant Neoplasm In The Colon →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07621159CT.gov A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07591597CT.gov A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07061210CT.gov An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06685276CT.gov Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06513221CT.gov A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab | — | Not Yet Recruiting | — | — | — |
NCT06282445CT.gov Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06231017CT.gov Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer | — | Unknown | — | — | — |
NCT06018714CT.gov Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm In The Colon
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adebrelimab (this asset) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | P2 | CCC · 52 |
| Binimetinib | Pierre Fabre Medicament | P3 | BB |
| Irinotecan | Oncolytics Biotech | P4 | BB |
| Aflibercept | Sanofi | P3 | BB |
| Adriamycin | Northwell Health | P4 | B |
| Durvalumab | University of Iowa | P2 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | Centre Georges Francois Leclerc | P2 | B |
| Famitinib | Jiangsu HengRui Medicine Co., Ltd. | P3 | B |
| Vemurafenib | Fudan University | P3 | B |
+42 more in the Metastatic Malignant Neoplasm In The Colon cohort
Other indications for Adebrelimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P4 | BB · 67 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adebrelimab in Metastatic Malignant Neoplasm In The Colon. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adebrelimab-metastatic-malignant-neoplasm-in-the-colon
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →